The U.S. Food and Drug Administration (FDA) has cleared Vektor Medical’s vMap system, a groundbreaking system that when paired with standard ECG practice, has the ability to construct a model of the patient’s heart electrophysiological activity using input from only a 12-lead electrocardiogram. By utilizing the combination between Vektor Medical’s novel system and traditional ECG procedure, the physician is able to chart arrhythmias in a noninvasive manner via production of both 2D and 3D diagrams in an incredibly short time period. Being that surgeons require knowledge of not only the presence of irregular heartbeats but also a visual map to locate the hotspots where these errors in electrical activity are occurring, Vektor’s system may aid in the reduction of time-intensive, complex testing such as CT scans, MRIs, or ultrasounds and requiring electrodes to be worn by the patient. Not only has the program displayed success in detecting atrial fibrillation along with a variety of cardiac arrhythmias, the company has previously shown that the vMap system has potential in assisting procedures, such as one for treating ventricular tachycardia. Results published in the Heart Rhythm Society’s journal provide support for vMap’s diagnostic capabilities, as VT sources in all seven of the study’s cases were localized successfully.  

Read more here